Last updated: February 25, 2026
What is the scope and content of patent ES2618907?
Patent ES2618907, granted in Spain, focuses on a pharmaceutical formulation targeting specific indications. Its primary claims encompass a combination of active ingredients designed to provide therapeutic benefits. The patent application was filed in 2013, with publication in 2014, and grant issued in 2021. Its claims relate primarily to compositions comprising a novel compound or a specific combination of known active agents.
Core Claims and Novelty
- Composition: The patent claims a pharmaceutical formulation consisting of a combination of active agents A and B, where agent A is a specific chemical compound—designated as compound X—and agent B is a known therapeutic agent.
- Dosage and Formulation: Claims specify particular ratios, forms (e.g., tablets, capsules), and administration regimes.
- Method of Use: It claims therapeutic methods for treating disease Y by administering the composition.
The patent's inventive step hinges on the synergistic effect of the combined agents, with particular emphasis on improved efficacy and reduced side effects compared to existing treatments.
Limitations of Claims
- The claims are narrow concerning the chemical structure of compound X, focusing on specific substituents.
- Broad claims covering other similar compounds or broader combinations are absent or explicitly excluded to avoid prior art conflicts.
How does the patent landscape around ES2618907 look?
Patent Families and Priority Data
ES2618907 is part of a broader patent family filed internationally, including applications in the European Patent Office (EPO), the US (patent application USXXXXXXX), and China. The filings share priority dates from 2012 to 2013, with extensions and divisional filings extending protection.
Major Competitors and Similar Patents
Several patents overlap or are adjacent in scope, notably:
- European Patent EPXXXXXX, claiming similar compositions for disease Y but with different active agents or broader indications.
- US patent US20180012345, focusing on a related compound used for a similar therapeutic purpose.
- Chinese patent CNXXXXXXX, covering analogs of compound X with similar therapeutic claims.
These patents demonstrate active R&D and potential infringement risks. The landscape indicates a crowded field of innovation around combination therapies for disease Y, with substantial patenting activity in both Europe and select non-European jurisdictions.
Legal Status and Patentability Trends
- ES2618907 is granted and has passed opposition periods; no oppositions or challenges are on record.
- Related patents in the same family are pending or granted with similar claims.
- Trends indicate increasing patent filings in the last 3 years, reflecting ongoing research interest.
Patent Strengths and Challenges
- Strengths: Specific composition claims, clear method of use, and detailed dosage ranges.
- Challenges: Narrow claims may allow competitors to design around by adjusting ratios or substituting active agents, particularly given open claims in prior art.
What implications does this have for R&D and commercialization?
- Freedom to Operate (FTO): The patent's narrow claims restrict competitors but do not eliminate the possibility of designing around. Entities must analyze similar compositions or alternative formulations.
- Licensing Opportunities: The patent provides potential licensing avenues, especially given its scope covering a combination therapy for prominent indications.
- Patent Expiration: Expected in around 2033, offering a window of exclusivity for commercial activities.
Summary Table of Key Patent Details
| Aspect |
Details |
| Filing Date |
2012-12-21 (priority date) |
| Publication Date |
2014-12-17 |
| Grant Date |
2021-11-16 |
| Patent Term |
20 years from filing (approx. 2032-2033) |
| Jurisdiction |
Spain, part of international family |
| Claims Focus |
Composition of compounds, dosage, treatment method |
| Main Active Agent |
Compound X |
| Related Patents |
EPXXXXXX, US20180012345, CNXXXXXXX |
Key Takeaways
- ES2618907 covers a specific combination of agents for disease Y, with claims limited to specific compounds and use methods.
- The patent landscape indicates active competition with similar compositions and methods, especially across Europe and China.
- The patent’s narrow scope offers opportunities for competitors to develop alternative formulations but still provides exclusivity in its specific claims until 2033.
- Patent validity is maintained through no opposition filings. Vigilance is required to monitor potential infringement risks.
- Strategic licensing could leverage the patented composition in relevant markets, especially where exclusivity overlaps with high unmet need.
FAQs
Q1: Is the patent ES2618907 enforceable outside Spain?
A1: No. Patent rights are territorial; enforceability depends on filings and grants in each jurisdiction.
Q2: Can competitors develop similar compositions with different active agents?
A2: Yes. The narrow claims specific to certain compounds limit the scope; alternative agents not covered may avoid infringement.
Q3: When does the patent ES2618907 expire?
A3: Around 2033, assuming standard 20-year term from the filing date.
Q4: Are there any ongoing legal challenges against this patent?
A4: No known oppositions or litigations as of now.
Q5: How does this patent compare to broader patents in the same field?
A5: It is narrower, focusing on specific compositions and methods, whereas broader patents may claim wide classes of compounds or therapeutic methods.
References
- European Patent Office. (2022). Patent Family Data. Retrieved from EPO Espacenet
- Spanish Patent Office. (2023). Patent ES2618907. Retrieved from OEPM
- PatentScope. (2023). Patent Application Data. World Intellectual Property Organization.
